JP2022535920A5 - - Google Patents
Info
- Publication number
- JP2022535920A5 JP2022535920A5 JP2021572548A JP2021572548A JP2022535920A5 JP 2022535920 A5 JP2022535920 A5 JP 2022535920A5 JP 2021572548 A JP2021572548 A JP 2021572548A JP 2021572548 A JP2021572548 A JP 2021572548A JP 2022535920 A5 JP2022535920 A5 JP 2022535920A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutical composition
- suramin
- less
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858621P | 2019-06-07 | 2019-06-07 | |
| US62/858,621 | 2019-06-07 | ||
| PCT/US2020/031217 WO2020247127A1 (en) | 2019-06-07 | 2020-05-02 | Compositions and methods for treating central nervous system disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535920A JP2022535920A (ja) | 2022-08-10 |
| JP2022535920A5 true JP2022535920A5 (cg-RX-API-DMAC7.html) | 2023-05-23 |
| JP7749169B2 JP7749169B2 (ja) | 2025-10-06 |
Family
ID=73652889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572548A Active JP7749169B2 (ja) | 2019-06-07 | 2020-05-02 | 中枢神経系障害を処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220226268A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3979985A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7749169B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114340597B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020288999A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3142842A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288655A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020247127A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021319064A1 (en) * | 2020-07-29 | 2023-03-23 | Perfect Daylight Limited | Methods of manufacture of suramin |
| US20230390223A1 (en) * | 2020-10-22 | 2023-12-07 | Paxmedica, Inc. | Administration of antipurinergic compositions for treating nervous system disorders |
| EP4229035A4 (en) * | 2020-10-22 | 2024-07-31 | Paxmedica, Inc. | INTRANASALY ADMINISTRATION OF SURAMIN FOR THE TREATMENT OF NERVOUS SYSTEM DISEASES |
| JP2024532288A (ja) * | 2021-08-23 | 2024-09-05 | パックスメディカ, インコーポレイテッド | 抗プリン作動薬を用いて神経系障害を処置するための方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5012285A (en) * | 1984-10-12 | 1986-05-02 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav) |
| JP2003506458A (ja) * | 1999-08-11 | 2003-02-18 | ジョセフ ピサ, | シクロデキストリン誘導体の包接複合体形成の増強 |
| JP2005519075A (ja) * | 2002-02-25 | 2005-06-30 | リフジャスロウン エイチエフ | 吸収促進剤 |
| FR2867682B1 (fr) * | 2004-03-22 | 2009-06-05 | Galderma Res & Dev | Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise. |
| US20070292523A1 (en) * | 2004-09-27 | 2007-12-20 | Joey Moodley | Dihydropyrimidine Formulations |
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| FR2912591B1 (fr) * | 2007-02-12 | 2009-05-01 | Oberthur Card Syst Sa | Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile. |
| AR062239A1 (es) * | 2007-08-07 | 2008-10-22 | Civil De Estudios Superiores A | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
| US20120070487A1 (en) * | 2010-03-24 | 2012-03-22 | Aegis Therapeutics Llc | Alkylsaccharide compositions with nutraceuticals |
| GB201401904D0 (en) * | 2014-02-04 | 2014-03-19 | Ziarco Pharma Ltd | Pharmaceutical composition for topical administration |
| FR3025110B1 (fr) * | 2014-09-02 | 2016-12-23 | Univ Francois-Rabelais De Tours | Dispositif de pulverisation nasale de produit fluide |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| HRP20250215T1 (hr) * | 2016-04-12 | 2025-06-20 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe |
| WO2018013811A1 (en) * | 2016-07-14 | 2018-01-18 | The Regents Of The University Of California | Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders |
| WO2018148262A1 (en) * | 2017-02-08 | 2018-08-16 | Csp Pharma, Inc. | Antipurinergic compounds and uses thereof |
| WO2018148580A1 (en) * | 2017-02-09 | 2018-08-16 | Perfect Daylight Limited | Methods for autism spectrum disorder pharmacotherapy |
| US11110060B2 (en) * | 2017-10-25 | 2021-09-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
-
2020
- 2020-05-02 JP JP2021572548A patent/JP7749169B2/ja active Active
- 2020-05-02 WO PCT/US2020/031217 patent/WO2020247127A1/en not_active Ceased
- 2020-05-02 US US17/615,673 patent/US20220226268A1/en not_active Abandoned
- 2020-05-02 EP EP20818146.1A patent/EP3979985A4/en active Pending
- 2020-05-02 CN CN202080055332.3A patent/CN114340597B/zh active Active
- 2020-05-02 CA CA3142842A patent/CA3142842A1/en active Pending
- 2020-05-02 AU AU2020288999A patent/AU2020288999A1/en not_active Abandoned
-
2021
- 2021-12-02 IL IL288655A patent/IL288655A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018204865B2 (en) | Anticonvulsant activity of steroids | |
| AU2023248120A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP6112867B2 (ja) | サキシトキシン誘導体での触覚の喪失の処置 | |
| KR102375232B1 (ko) | 비강내 에피네프린 제제 및 질환의 치료 방법 | |
| AU2017379247A1 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| CN102159244A (zh) | 包含减充血剂和皮质类固醇的鼻内组合物 | |
| JP2020502215A (ja) | Task−1およびtask−3チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用 | |
| AU2008259864B2 (en) | Methods and compositions for administration of Oxybutynin | |
| JP6934581B2 (ja) | エピナスチン又はその塩を含有する水性医薬組成物 | |
| JP2023546923A5 (cg-RX-API-DMAC7.html) | ||
| MX2010014223A (es) | Composiciones pediatricas para el tratamiento de esclerosis multiple. | |
| KR20240069750A (ko) | 신경 장애의 치료 | |
| CA3124202A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
| CN114903840A (zh) | 一种治疗抑郁症的低剂量r-氯胺酮经鼻药物 | |
| US10966988B2 (en) | Method for smoking cessation | |
| WO2025196662A1 (en) | Compositions and methods for treating eating disorders | |
| KR20230031214A (ko) | 적응 장애의 치료 | |
| JP2025160345A (ja) | 薬学的組成物 | |
| EP3338764A1 (de) | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen | |
| WO2025022362A1 (en) | Compositions and methods for treating dyskinesia | |
| TW201717936A (zh) | 噴霧器用組成物 | |
| EP4329722A1 (en) | Use of perillyl alcohol to enhance levo-dopa delivery | |
| HK40091740A (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| HK40020052A (en) | Negundo chastetree oil solution preparation for inhalation and preparation method thereof | |
| HK1260775B (en) | Methods of increasing tonic inhibition and treating angelman syndrome |